(Q54329544)

27 May 2018

title

Importance of inducible multidrug resistance 1 expression in HL-60 cells resistant to gemtuzumab ozogamicin. (English)

1 reference

27 May 2018

main subject

multiple drug resistance

1 reference

Taichi Matsumoto

1

1 reference

27 May 2018

Shiro Jimi

2

1 reference

27 May 2018

Shuuji Hara

3

1 reference

27 May 2018

Yasushi Takamatsu

4

1 reference

27 May 2018

Junji Suzumiya

5

1 reference

27 May 2018

Kazuo Tamura

6

1 reference

27 May 2018

publication date

13 February 2012

1 reference

27 May 2018

published in

Leukemia & Lymphoma

1 reference

27 May 2018

volume

53

1 reference

27 May 2018

issue

7

1 reference

27 May 2018

page(s)

1399-1405

1 reference

27 May 2018

Gemtuzumab ozogamicin, a potent and selective anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia.

cites work

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.656102

Calicheamicin-DNA complexes: warhead alignment and saccharide recognition of the minor groove

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.656102

Calicheamicin-conjugated humanized anti-CD33 monoclonal antibody (gemtuzumab zogamicin, CMA-676) shows cytocidal effect on CD33-positive leukemia cell lines, but is inactive on P-glycoprotein-expressing sublines.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.656102

CD33 expression and P-glycoprotein-mediated drug efflux inversely correlate and predict clinical outcome in patients with acute myeloid leukemia treated with gemtuzumab ozogamicin monotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.656102

Multidrug resistance protein attenuates gemtuzumab ozogamicin-induced cytotoxicity in acute myeloid leukemia cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.656102

Tumour stem cells and drug resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.656102

Reduced effect of gemtuzumab ozogamicin (CMA-676) on P-glycoprotein and/or CD34-positive leukemia cells and its restoration by multidrug resistance modifiers

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.656102

Pilot study of gemtuzumab ozogamicin, liposomal daunorubicin, cytarabine and cyclosporine regimen in patients with refractory acute myelogenous leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.656102

Gemtuzumab ozogamicin, fludarabine, cytarabine and cyclosporine combination regimen in patients with CD33+ primary resistant or relapsed acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.656102

Gemtuzumab, fludarabine, cytarabine, and cyclosporine in patients with newly diagnosed acute myelogenous leukemia or high-risk myelodysplastic syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.656102

Multidrug transporter proteins and cellular factors involved in free and mAb linked calicheamicin-gamma1 (gentuzumab ozogamicin, GO) resistance and in the selection of GO resistant variants of the HL60 AML cell line

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.656102

Multidrug resistance in cancer: role of ATP-dependent transporters

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.656102

Transcriptional regulation of ABC drug transporters

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.656102

Multidrug-resistance phenotype and clinical responses to gemtuzumab ozogamicin

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.656102

Induction of multidrug resistance in MOLT-4 cells by anticancer agents is closely related to increased expression of functional P-glycoprotein and MDR1 mRNA.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.656102

Expression of a P-glycoprotein gene is inducible in a multidrug-resistant human leukemia cell line

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.656102

Inhibition of the mitogen-activated protein kinase pathway results in the down-regulation of P-glycoprotein

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.656102

Transcriptional repression of protein kinase Calpha via Sp1 by wild type p53 is involved in inhibition of multidrug resistance 1 P-glycoprotein phosphorylation

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.656102

Reversal of P-glycoprotein-mediated multidrug resistance in cancer cells by the c-Jun NH2-terminal kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.656102

10.3109/10428194.2012.656102

21 January 2018

Identifiers

DOI

1 reference

27 May 2018

1 reference

27 May 2018